Together, these results suggest that vaccine-induced targeting of spliced HIV-1 peptides could provide a novel strategy for enhancing CD8+ T cell response breadth beyond that achieved during natural infection to facilitate HIV prophylaxis and therapy. The gene discussed is CD8A; the disease is infection.